Immortalized Human Bone Marrow-Derived Mesenchymal Stem Cells-SV40T

Immortalized Human Bone Marrow-Derived Mesenchymal Stem Cells (hBM-MSCs), engineered through the stable transduction of the Simian Virus 40 Large T antigen (SV40T), represent a transformative tool for regenerative medicine and therapeutic development. While primary BM-MSCs are the "gold standard" in stem cell research, they are severely limited by donor-dependent variability and rapid in vitro senescence. Our SV40T-immortalized line effectively bypasses these constraints, providing a continuous, standardized, and highly proliferative cell population.

• Extended Proliferative Longevity: The integration of SV40T neutralizes the p53 and pRb pathways, ensuring indefinite expansion capabilities. This provides an inexhaustible cell source that eliminates the "culture fatigue" typical of primary MSCs, ensuring long-term experimental consistency.
• Maintenance of Multipotency: Despite their enhanced growth kinetics, these cells strictly retain their tri-lineage differentiation potential. They can be robustly induced into osteogenic, chondrogenic, and adipogenic lineages, making them ideal for tissue engineering and bone metabolism studies.
• Conserved Immunomodulatory Profile: Our hBM-MSCs maintain the hallmark low-immunogenicity (MHC Class I expression without MHC Class II) and characteristic surface markers (CD73+, CD90+, CD105+). They remain a high-fidelity model for investigating paracrine signaling and immunosuppressive mechanisms.
• Scalable Biopharmaceutical Platform: The line serves as a superior substrate for secretome analysis, exosome production, and viral vector manufacturing. Its standardized nature significantly reduces the technical noise associated with primary donor heterogeneity, accelerating the path from bench to clinical transition.

Engineered for precision and scalability, the Immortalized hBM-MSCs (SV40T) bridge the gap between basic stem cell biology and high-throughput industrial applications. This product is an essential asset for labs focusing on drug screening, gene therapy delivery, and the development of next-generation cell-based therapeutics.